Menu
Science and research

Professional Publications

Author
Title
Year of publication

Publications (2655)

[21]

Pagano, M.; Pepperkok, R.; Lukas, J.; Baldin, V.; Ansorge, W.; Bartek, J.; Draetta, G.

Regulation of the cell cycle by the cdk2 protein kinase in cultured human fibroblasts

[year of publication 2006, impact factor 11.700]

[22]

Penicka, M.; Widimsky, P.; Kobylka, P.; Kozak, T.; Lang, O.

Early tissue distribution of bone marrow mononuclear cells after transcoronary transplantation in a patient with acute myocardial infarction.

[year of publication 2006, impact factor 11.632]

[23]

Penicka, M.; Horak, J.; Kobylka, P.; Pytlik, R.; Kozak, T.; Belohlavek, O.; Lang, O.; Skalicka, H.; Simek, S.; Palecek, T.; Linhart, A.; Aschermann, M.; Widimsky, P.

Intracoronary injection of autologous bone marrow-derived mononuclear cells in patients with large anterior acute myocardial infarction : a prematurely terminated randomized study

[year of publication 2008, impact factor 11.054]

[24]

Goodeve, A.C.; Eikenboom, J.; Castaman, G.; Rodeghiero, F.; Federici, A.B.; Batlle, J.; Meyer, D.; Mazurier, C.; Goudemand, J.; Schneppenheim, R.; Budde, U.; Ingerslev, J.; Habart, D.; Vorlova, Z.; et. al.

Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD)

[year of publication 2012, impact factor 10.896 ]

[25]

Standeven, K.F.; Carter, A.M.; Grant, P.J.; Weisel, J.W.; Chernysh, I.; Masova, L.; Lord, S.T.; Ariens, R.A.S.

Functional analysis of fibrin gamma-chain cross-linking by activated factor XIII : determination of a cross-linking pattern that maximizes clot stiffness

[year of publication 2008, impact factor 10.896]

[26]

Malaspina, P.; Cruciani, F.; Ciminelli, B.M.; Terrenato, L.; Santolamazza, P.; Alonso, A.; Banyko, J.; Brdicka, R.; Garcia, O.; Gaudiano, C.; Guanti, G.; Kidd, K.K.; Lavinha, J.; Avila, M.; Mandich, P.; Moral, P.; Qamar, R.; Mehdi, S.Q.; Ragusa, A.; Stefanescu, G.; Caraghin, M.; Tyler-Smith, C.

Network analyses of Y-chromosomal types in Europe, Northern Africa, and Western Asia reveal specific patterns of geographic distribution

[year of publication 2006, impact factor 10.869]

[27]

Andre, P.; Hartwell, D.; Hrachovinova, I.; Saffaripour, S.; Wagner, D.D.

Pro-coagulant state resulting from high levels of soluble P-selectin in blood

[year of publication 2010, impact factor 10.789]

[28]

Lukas, J.; Petersen, B.O.; Holm, K.; Bartek, J.; Helin, K.

Deregulated expression of E2F family members induces S-phase entry and overcomes p16INK4A-mediated growth suppression

[year of publication 2006, impact factor 10.727]

[29]

Lukas, J.; Bartkova, J.; Bartek, J.

Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint

[year of publication 2006, impact factor 10.727]

[30]

Müller, H.; Lukáš, J.; Schneider, A.; Warthoe, P.; Bártek, J.; Eilers, M.; Strauss, M.

Cyclin-D1 expression is regulated by the retinoblastoma protein

[year of publication 2006, impact factor 10.667]

[31]

Satoh, T.; Satoh, H.; Iwahara, S.I.; Hrkal, Z.; Peyton, D.H.; Muller-Eberhard, U.

Roles of heme iron-coordinating histidine residues of human hemopexin expressed in baculovirus-infected insect cells

[year of publication 2006, impact factor 10.667]

[32]

Peslova, G.; Petrak, J.; Kuzelova, K.; Hrdy, I.; Halada, P.; Kuchel, P.W.; Soe-Lin, S.; Ponka, P.; Sutak, R.; Becker, E.; Huang, M.L.-H.; Rahmato, Y.S.; Richardson, D.R.; Vyoral, D.

Hepcidin, the hormone of iron metabolism, is bound specifically to alpha-2-macroglobulin in blood

[year of publication 2009, impact factor 10.555]

[33]

Lukas, J.; Bartkova, J.; Rohde, M.; Strauss, M.; Bartek, J.

Cyclin D1 is dispensable for G(1) control in retinoblastoma gene-deficient cells independently of cdk4 activity

[year of publication 2006, impact factor 10.498]

[34]

Forestier, E.; Izraeli, S.; Beverloo, B.; Haas, O.; Pession, A.; Michalová, K.; Stark, B.; Harrison, C.J.; Teigler-Schlegel, A.; Johansson, B.

Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome : an iBFM-SG study

[year of publication 2008, impact factor 10.432]

[35]

Porkka, K.; Koskenvesa, P.; Lundán, T.; Rimpiläinen, J.; Mustjoki, S.; Smykla, R.; Wild, R.; Luo, R.; Arnan, M.; Brethon, B.; Eccersley, L.; Hjorth-Hansen, H.; Höglund, M.; Klamová, H.; Knutsen, H.; Parikh, S.; Raffoux, E.; Gruber, F.; Brito-Babapulle, F.; Dombret, H.; Duarte, R.F.; Elonen, E.; Paquette, R.; Zwaan, C.M.; Lee, F.Y.

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia

[year of publication 2008, impact factor 10.432]

[36]

Haberichter, S.L.; Castaman, G.; Budde, U.; Peake, I.; Goodeve, A.; Rodeghiero, F.; Federici, A.B.; Batlle, J.; Meyer, D.; Mazurier, C.; Goudemand, J.; Eikenboom, J.; Schneppenheim, R.; Ingerslev, J.; Vorlova, Z.; Habart, D.; Holmberg, L.; Lethagen, S.; Pasi, J.; Hill, F.G.H.; Montgomery, R.R.

Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the european study: Molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD)

[year of publication 2010, impact factor 10.432]

[37]

Castaman, G.; Lethagen, S.; Federici, AB.; Tosetto, A.; Goodeve, A.; Budde, U.; Batlle, J.; Meyer, D.; Mazurier, C.; Fressinaud, E.; Goudemand, J.; Eikenboom, J.; Schneppenheim, R.; Ingerslev, J.; Vorlova, Z.; Habart, D.; Holmberg, L.; Pasi, J.; Hill, F.; Peake, I.; Rodeghiero, F.

Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD

[year of publication 2010, impact factor 10.432]

[38]

Goodeve, A.

Erratum: Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD) (Blood (2007) 109 (112-121))

[year of publication 2012, impact factor 10.432 ]

[39]

Ho, G.Y.F.; Burk, R.D.; Klein, S.; Kadish, A.S.; Chang, C.J.; Palan, P.; Basu, J.; Tachezy, R.; Lewis, R.; Romney, S.

Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia

[year of publication 2006, impact factor 10.165]

[40]

Curik, N.; Burda, P.; Vargova, K.; Pospisil, V.; Belickova, M.; Vlckova, P.; Savvulidi, F.; Necas, E.; Hajkova, H.; Haskovec, C.; Cermak, J.; Krivjanska, M.; Trneny, M.; Laslo, P.; Jonasova, A.; Stopka, T.

5-Azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity

[year of publication 2012, impact factor 10.164 ]


Quick contact

Head of Science and Research Division
Tel:+420 221 977 208

Deputy head of Science and Research Division
Tel:+420 221 977 269
Tel:+420 221 977 364

Secretary
Tel:+420 221 977 247


Opening hours

Ambulance
Mo – Fr: 7:00–18:00
Weekends: 9:00–13:00

Donors
Mo – Fr: 7:00–10:30

Visitors
Inpatient department
Mo – Fr: 13:00–18:00

ICU and Transplant unit
Mo – Fr: 14:00–17:00

How to find us

map

Ústav hematologie a krevní transfuze
(​Institute of Hematology and Blood Transfusion)

U Nemocnice 2094/1
128 00 Praha 2

The nearest underground station: Karlovo náměstí (line B)

The nearest tram station: Karlovo náměstí (10, 16, 22), Moráň (3, 6, 10, 16, 18, 24)

The nearest bus station: U Nemocnice (148), Karlovo náměstí (176)

How to get here